New York, May 26, 2026, 05:04 (EDT)
- OABI was quoted at $2.65 in early U.S. premarket trade; the stock closed Friday at $2.65, up 3.92%.
- Nasdaq was closed Monday for Memorial Day, putting Friday’s 52-week high back in focus as regular trading resumes Tuesday.
- Investors have a short catalyst window: Benchmark investor meetings on May 28 and ASCO-related partner updates starting May 29.
OmniAb Inc shares were steady in early U.S. premarket trade Tuesday after the antibody-discovery company ended the last regular session at a 52-week high, extending a sharp May rally in the Nasdaq-listed stock. OABI was quoted at $2.65 before the bell; StockAnalysis listed Friday’s close at $2.65, with an intraday high of $2.73 and volume of 710,795 shares. Premarket means trading before the regular 9:30 a.m. New York open, and it can be thin.
The timing matters. U.S. equity markets were closed Monday, May 25, for Memorial Day, according to Nasdaq’s 2026 holiday schedule, so Tuesday gives traders the first full chance to test whether last week’s 21.6% advance holds up after the long weekend.
The stock move is still tied to OmniAb’s May 7 update, not a fresh overnight company filing. OmniAb reported first-quarter revenue of $14.4 million, up from $4.2 million a year earlier, and raised its 2026 revenue guidance to $28 million to $33 million from $25 million to $30 million.
Chief Executive Matt Foehr said the quarter showed “strong momentum” as multiple partner programs advanced into later-stage clinical development, adding that the company was raising guidance after “a very strong start to the year.” Business Wire
The core issue is milestone revenue. In plain terms, these are payments triggered when a partner hits a contracted development, regulatory or commercial goal. OmniAb’s quarterly filing showed license and milestone revenue rose to $12.0 million from $2.0 million a year earlier, and the company said the increase was mainly due to a $10.0 million rise in milestone revenue.
Chief Financial Officer Kurt Gustafson was careful about the cadence. He said revenue is still largely driven by milestones, which can be “highly variable in any given quarter,” while adding that partner-program growth should generally support higher milestone revenue over time. The Motley Fool
OmniAb had 107 active partners and 409 active programs as of March 31, including 27 OmniAb-derived antibodies in clinical development, two under regulatory review and three approved products commercialized by partners. That breadth is the bull case: more shots on goal can mean more future milestone and royalty income, with royalties being a share of product sales after commercialization.
Costs are still part of the story. The company posted a net loss of $7.7 million, or 6 cents a share, but that narrowed from a loss of $18.2 million, or 17 cents a share, a year earlier. Its cash, cash equivalents and short-term investments stood at $49.1 million at March 31, and the company said that was enough to support operations for at least 12 months from the filing date.
The peer read is mixed, and comparisons are imperfect. AbCellera Biologics also operates in antibody drug creation, while Xencor is built around an antibody and protein-engineering platform; both give investors reference points for platform-biotech valuations, but OmniAb’s immediate price action is more closely tied to partner milestones than to a wholly owned clinical readout.
But the setup can turn quickly. OmniAb said license and milestone revenue can swing sharply with the timing of partner agreements and partner milestones, and its filing notes that the company does not control partners’ clinical development, regulatory strategy or commercialization decisions. A delayed trial, a quiet partner update or a failed program could cool the run.
The week ahead gives the stock two near-term markers. OmniAb’s investor calendar lists the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference on May 28, while the company has said multiple partner programs are expected to be highlighted at the ASCO Annual Meeting running May 29 to June 2.
For now, OABI is less an index story than a test of whether investors keep paying up for a small-cap platform name whose earnings power depends on other companies moving drugs through the clinic. That is the trade in front of Tuesday’s open.
